Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 30 versus DEXTROSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 30 versus DEXTROSTAT.
ADDERALL 30 vs DEXTROSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Dextroamphetamine is a central nervous system stimulant that promotes release of dopamine and norepinephrine from presynaptic neurons, and inhibits their reuptake, thereby increasing synaptic concentrations of these neurotransmitters.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
5-60 mg orally per day in divided doses, typically 5-10 mg 2-3 times daily, maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Terminal elimination half-life is approximately 10-13 hours in adults, 6-8 hours in children. Extended duration allows once-daily dosing in some patients.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
Primarily renal (approximately 90% as unchanged drug and metabolites); minor biliary/fecal elimination (<10%).
Category C
Category C
CNS Stimulant
CNS Stimulant